A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine

Inclusion criteria

(All Cohorts): * Males and females, 18 to 75 years old, inclusive * Body mass index (BMI) 18 to 40 kg/m2, inclusive, at Screening * Females of child-bearing potential must have a negative pregnancy test at Screening and on Day -1 (Cohort A) or Day -6 (Cohort B) and must agree to use highly effective contraception methods from Screening throughout the duration of the Treatment Period and for 14 days following the last dose of study drug Inclusion criteria (Cohort A \[Healthy subjects with normal renal function\] only): * Estimated creatinine clearance (CLCR), according to the Cockcroft-Gault (C-G) equation, ≥ 90 mL/min at Screening * Age, BMI, and sex comparable to those of subjects of Cohort B * Good health status as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations Inclusion criteria (Cohort B, Severe RI): * Diagnosis of CKD * Estimated glomerular filtration rate (eGFR), according to the Modification of Diet in Renal Disease (MDRD) equation, \< 30 mL/min/1.73 m2 (and not receiving dialysis) * Stable medication dose and dosing regimen for treatment of the complications of renal disease or other concomitant chronic illnesses for at least 2 weeks prior to study drug administration